VENT-03

DRUG2 trials

Sponsors

Ventus Therapeutics U.S. Inc., Ventus Therapeutics U.S., Inc.

Conditions

CLECutaneous Lupus ErythematosusCutaneous Lupus Erythematosus (CLE)SLESLE (Systemic Lupus)Systemic Lupus Erythematosus

Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Not yet recruitingCTIS2024-520098-12-00

Ventus Therapeutics U.S. Inc.Cutaneous Lupus Erythematosus

Target: 13Updated: 2025-12-08

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

RecruitingNCT07260877

Ventus Therapeutics U.S., Inc.CLE, Cutaneous Lupus Erythematosus (CLE), SLE +2

Start: 2025-12-03End: 2026-09-01Target: 24Updated: 2026-07-27